Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников
Шрифт:
76. Dyer, Owen, 2003. Aspirin could be used to prevent cancer. BMJ, 326, 565.
77. Flower, Rod, 2003. What are all the things that aspirin does? BMJ, 327, 572–573.
78. UK limits use of aspirin by under 16s. BMJ, 2002, 324, 1294.
79. Astralagus. ICON, 2002, 1 (3), 23.
80. Bartram, Т., 1998. Bartram’s encyclopedia of herbal medicine. Robinson publishing.
81. Campbell, T.C. and Campbell, T.M., 2006. The China Study. Benbella Books.
82. Greenwald, Peter, 2002. Cancer chemoprevention. BMJ, 324, 714–718.
Дополнение
1. Clarke, M.F. and Becker, M.W, 2006. Stem cells: the real culprits in cancer? Scientific American, July 2006, 53–59.
2. Study reveals how growth factors affect human stem cells. www.hhmi.org/news/melton.hmtl
3. Murray, R.K., Granner, D.K., Mayes, P.A. and Rodwell, VW, 1990. Harper's Biochemistry. Appleton and Lange Norwalk, CT, p. 653.
4. Woolf, Neville, 1998. Pathology, Basic and Systemic. WB. Saunders Publishing Co., Chapter 28, p. 274, Figure 28.
5. www.intouchlive.com/cancergenetics/onco.htm
6. Ludwig, Т., Fisher, P., Ganesan, S. and Efstratiadis, 2001. Tum-origenesis in mice carrying a truncating BRCA1 mutation. Genes and Development, Vol. 15 (10), 1188–1193.
7. Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, Т., Hennighausen, L., Wynshaw-Boris, A. and Deng, C.X. 1999. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, Vol. 22 (1), 37–43.
8. Pauli, T.T, Cortez, D., Bowers, B., Elledge, S.J. and Geliert, M., 2001. Direct DNA binding by BRCA1. Proceedings of the National Academy of Sciences of the USA, Vol. 98 (11), 6086–6091.
9. Jensen, R.A., Thompson, M.E., Jetton, T.L., Szabo, C.I., van der Meer, R., Helou, В., Tronick, S., King, M.C., Page, D.L. and Holt, J.T., 1996. BRCA1 is secreted and exhibits properties of a granin. Nature Genetics, 12, 303–308; www.mc.vander-bilt.edu/cancer/research/ roster/jensen.html
10. Struewing, J.P., Abeliovich, D., Peretz, Т., Avishai, N., Kaback, M.M., Collins, F.S. and Brody, L.C., 1995. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nature Genetics, 11, 198–200;
http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html
11. Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S., 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14, 185–187; Oddoux, C., Struewing, J.P., Clayton, C.M., Neuhausen, S., Vrody, L.C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., Golgar, D., Ostrer, H. and Offit, K., 1996. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %. Nature Genetics, 14, 188–190; http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html
12. www.mercola.com/2002/apr/27/sv40.htm
13. Hursting, S.D., Slaga,T.J., Fischer, S.M., DiGiovanni, J. and Phtans, J. M., 1999. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Journal of the National Cancer Institute, 35, 2031–2038.
14. Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.
15. Cheesernan, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.
16. Stewart, H.J., 1989. Clinical experience in the use of antioestrogen tamoxifen in the treatment of breast cancer. Proceedings of the Royal Society of Edinburgh, 95B, 231–237.
17. Miller, W R., 1997. Aromatase inhibitors and breast cancer. Cancer Treatment Reviews, 23, 113–131.
18. Dao, T.L., Sinha, D.K., Nemato, T. and Patel, J., 1982. Effects of estrogens and progesterone on cellular replication of human breast tumours. Cancer Research, 42, 359–362.
19. Conte, P.P., Fraschini, G. and Dewinko, B., 1985. Estrogen induced expansion of the growth fraction in receptor negative human breast cancer.Journal of Steroid Biochemistry, 23, 1169–1172.
20. Miller, WR. and Langdon, S.P., 1997. Hormonal, growth factor and cytokine control of breast cancer. In: Biology of Female Cancers, pp. 43–60. Langdon, S,P., Miller, WR. and Berchuck, A. (editors). New York: CRC Press.
21. Miller, WR., 1991. Oestrogens and breast cancer: biological considerations, British Medical Bulletin, 47, 470–483.
22. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.
23. Rose, Steven, with Mileusnic, Radmila, 1999. The Chemistry of Life. Fourth (revised) edition. Penguin Books.
24. Voet, Donald and Voet, Judith, 1995. Biochemistry. Second edition. John Wiley & Sons, Inc.
25. Jiang, Wen G., Matsumoto, Kunio and Nakamura, Toshikazu (editors), 2001, Growth Factors and their Receptors in Cancer Metastasis. Dordrecht: Kluwer Academic Publishers.
26. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.
27. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.
28. www.ucop.edu/srphome/bcrp/progressreport/abstracts/ innov/3CB-0186.html
29. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.